risperidone and Obesity studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

Excerpt	Relevance	Reference
"1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2."	9.12	Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006)
"In this post hoc analysis of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder, the metabolic syndrome was highly prevalent at baseline."	9.11	Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005)
"Atypical antipsychotics such as risperidone cause drug-induced metabolic syndrome."	8.02	The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. ( Arnold, AG; Birnbaum, SG; Chen, X; Jia, L; Li, L; Li, X; Liu, C; Sohn, JW; Wan, R; Wyler, SC; Yoo, ES, 2021)
"To analyze weight gain, metabolic hormones, and homocysteine (Hcys) levels in children and adolescents on antipsychotics (AP) during a year-long follow-up."	7.85	The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. ( Arango, C; Baeza, I; Calvo-Escalona, R; Castro-Fornieles, J; de la Serna, E; Merchán-Naranjo, J; Rodríguez-Latorre, P; Vigo, L, 2017)
"Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity."	7.76	[Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010)
"The results of this observational study indicate that, in Asian patients with schizophrenia, olanzapine may offer benefits when compared with typical agents or risperidone."	7.73	Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. ( Dyachkova, Y; Habil, H; Lee, C; Lee, P; Wu, KH, 2006)
"Treatment with olanzapine was associated with significantly greater weight gain than treatment with risperidone in Chinese schizophrenia patients in Hong Kong."	7.72	Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. ( Lee, E; Leung, CM; Wong, E, 2004)
"Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia."	6.73	Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007)
"Risperidone was switched to another antipsychotic."	5.34	Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female. ( Afzal, KI; Briones, DF; DeVargas, C, 2007)
"TEAM was a multi-site, 8-week, randomized clinical trial of risperidone, lithium, or divalproex in 279 medication-naïve patients, aged 6 through 15 years, with a DSM-IV diagnosis of bipolar disorder currently in manic or mixed phase."	5.16	Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. ( Axelson, DA; Birmaher, B; Emslie, G; Joshi, P; Luby, J; Riddle, MA; Robb, A; Ryan, ND; Tillman, R; Vitiello, B; Wagner, KD; Walkup, JT; Yenokyan, G, 2012)
" We examined changes in weight and weight-related quality of life among community patients with schizophrenia treated with aripiprazole (ARI) versus standard of care (SOC), consisting of other marketed atypical antipsychotics (olanzapine, quetiapine, and risperidone)."	5.13	Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. ( Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD, 2008)
"1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2."	5.12	Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006)
"In this post hoc analysis of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder, the metabolic syndrome was highly prevalent at baseline."	5.11	Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005)
"This 14-week, multicenter, open-label, rater-blinded, randomized study evaluated the effects of a group-based behavioral treatment (BT) for weight loss in overweight and obese stable patients with DSM-IV schizophrenia or schizoaffective disorder who had been switched from olanzapine to risperidone."	5.11	Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. ( Berry, S; Brar, JS; Ganguli, R; Mahmoud, R; Pandina, G; Turkoz, I, 2005)
"Clozapine and olanzapine caused the most weight gain, risperidone was intermediate, and sertindole had less associated weight gain than haloperidol."	5.09	Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999)
"The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)."	4.98	Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018)
" This reveals that the atypical antipsychotics are most likely to induce weight gain, in particular clozapine and olanzapine."	4.82	[Psychotropics and weight gain]. ( Bryois, Ch; Sahli, Ch, 2004)
"Atypical antipsychotics such as risperidone cause drug-induced metabolic syndrome."	4.02	The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. ( Arnold, AG; Birnbaum, SG; Chen, X; Jia, L; Li, L; Li, X; Liu, C; Sohn, JW; Wan, R; Wyler, SC; Yoo, ES, 2021)
" In this study, 264 Han Chinese inpatients diagnosed with schizophrenia or schizoaffective disorder initiated treatment with olanzapine (n=131) or risperidone (n=133) and were followed for 12weeks."	3.88	T ( Gao, M; Gao, Y; He, Y; Jiang, R; Li, J; Li, S; Li, WD; Lv, H; Wang, L; Wang, X; Xu, C; Zhang, M, 2018)
"To analyze weight gain, metabolic hormones, and homocysteine (Hcys) levels in children and adolescents on antipsychotics (AP) during a year-long follow-up."	3.85	The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. ( Arango, C; Baeza, I; Calvo-Escalona, R; Castro-Fornieles, J; de la Serna, E; Merchán-Naranjo, J; Rodríguez-Latorre, P; Vigo, L, 2017)
"A 17-year-old girl gained more than 25 kg in weight during treatment with risperidone and subsequently developed headache, diplopia and loss of vision due to IIH."	3.81	[Idiopathic intracranial hypertension and obesity]. ( Braakman, HM; Naarden, MT; Porro, GL; Schuitemaker, A; Straver, JS; van Doormaal, TP, 2015)
"To determine the risk of developing obesity and related metabolic complications in children following long-term treatment with risperidone or quetiapine."	3.81	Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015)
" The calorie-restricted diet was not significantly associated with a reduction in weight gain in participants who received any of the atypical antipsychotic agents except for olanzapine; therefore, findings indicate that the calorie-restricted diet may only be effective for patients receiving olanzapine."	3.80	The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications. ( Derbabian, B; Jacobowitz, W; Saunders, A, 2014)
"Risperidone-induced weight gain is associated with hyperphagia and a reduction in locomotor activity in C57BL/6J mice."	3.79	Effects of risperidone on energy balance in female C57BL/6J mice. ( Allison, DB; Johnson, MS; Kesterson, RA; Li, X; Li, Y; Nagy, TR; Smith, DL, 2013)
"Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity."	3.76	[Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010)
"We investigated the relationships between functional genetic variants of the 5-HT(2C) receptor and multidrug-resistant protein (MDR1), coding for P-glycoprotein, and second generation antipsychotic (SDA)-induced weight gain among 108 female schizophrenic patients treated with olanzapine or risperidone for up to 4 months."	3.74	The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. ( Bilusic, H; Bozina, N; Hotujac, L; Kuzman, MR; Medved, V; Sain, I, 2008)
"The results of this observational study indicate that, in Asian patients with schizophrenia, olanzapine may offer benefits when compared with typical agents or risperidone."	3.73	Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. ( Dyachkova, Y; Habil, H; Lee, C; Lee, P; Wu, KH, 2006)
" Role of ghrelin (RIA), resistin and TNF-alpha (ELISA) in weight gain and insulin resistance (fasting plasma insulin, HOMA, ELISA) was studied in Hungarian psychiatryic patients (n=60) treated with SGA (clozapine, olanzapine, risperidone, quetiapine, 15 each)."	3.73	[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics]. ( Birkás Kováts, D; Cseh, K; Faludi, G; Palik, E, 2005)
" Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis."	3.73	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. ( Allison, DB; Anderson, EJ; Borba, CP; Cagliero, E; Copeland, PM; Daley, TB; Evins, AE; Goff, DC; Hayden, D; Henderson, DC; Schoenfeld, D; Weber, MT, 2005)
" To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis."	3.73	Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006)
"Treatment with olanzapine was associated with significantly greater weight gain than treatment with risperidone in Chinese schizophrenia patients in Hong Kong."	3.72	Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. ( Lee, E; Leung, CM; Wong, E, 2004)
"The study population comprised 56 patients with DSM-IV schizophrenia, who were divided into 4 treatment groups: quetiapine (N = 14), olanzapine (N = 14), risperidone (N = 14), or clozapine (N = 14) monotherapy, and a control group of 11 patients receiving no psychopharmacologic treatment."	3.72	Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003)
"Elderly patients with Alzheimer's disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects."	2.74	Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. ( Dagerman, KS; Hsiao, JK; Lebowitz, BD; Lyketsos, CG; Mack, WJ; Schneider, LS; Stroup, TS; Sultzer, DL; Tariot, PN; Vigen, C; Zheng, L, 2009)
"Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia."	2.73	Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007)
" Based on recent criteria for pediatric populations, patients were considered "at risk for adverse health outcome" if they met at least 1 of the following criteria: (1) > or = 85th BMI percentile plus presence of 1 or more negative weight-related clinical outcomes, or (2) > or = 95th BMI percentile."	2.73	Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. ( Arango, C; Cifuentes, A; Fraguas, D; Giráldez, M; Laita, P; Merchán-Naranjo, J; Moreno, D; Parellada, M; Ruiz-Sancho, A, 2008)
" Safety was assessed using the Extrapyramidal Symptom Rating Scale (ESRS), clinical laboratory tests, electrocardiograms, and the recording of adverse events, vital signs, Tanner score, and changes in body mass index (BMI)."	2.72	Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. ( Augustyns, I; Csaba, K; Eerdekens, M; Olah, R; Reyes, M, 2006)
"Risperidone was the most commonly prescribed SGA (n = 99; 41%; average daily dose 1."	1.46	Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis. ( Fabian, TJ; Kibler, AV; Nolt, VD; Wilkening, GL, 2017)
"Authors identified different types of eating disorders: external, restrictive and emotiogenic as well as the relationship of their prevalence and severity with sex, drug, presence and grade of obesity."	1.42	[Eating disorders in psychiatric patients during treatment with second generation antipsychotics]. ( Bulanov, VS; Gorobets, LN; Ivanova, GP; Litvinov, AV; Polyakovskaya, TP; Tsarenko, MA; Vasilenko, LM, 2015)
"Risperidone was switched to another antipsychotic."	1.34	Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female. ( Afzal, KI; Briones, DF; DeVargas, C, 2007)
"Risperidone was the most commonly cited agent."	1.33	Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? ( Pandurangi, A; Silverman, JJ; Sood, AB; Vieweg, WV, 2005)
" Mice were acclimated to individual housing, given ad libitum access to chow and water, dosed with placebo peanut butter pills for 1 week, and then dosed daily with AAPD-laced peanut butter pills for 4 weeks."	1.33	Antipsychotic drug-induced weight gain: development of an animal model. ( Allison, DB; Casey, DE; Cope, MB; Fernández, JR; Geary, N; Nagy, TR, 2005)
"Drug-induced weight gain is a serious side effect of many commonly used drugs leading to noncompliance with therapy and to exacerbation of comorbid conditions related to obesity."	1.33	Drug-induced weight gain. ( Apovian, CM; Ness-Abramof, R, 2005)
"Olanzapine-treated patients had significantly higher plasma triglyceride concentrations (2."	1.32	Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. ( Alméras, N; Bouchard, RH; Cadrin, C; Demers, MF; Després, JP; Mottard, JP; Roy, MA; Villeneuve, J, 2004)
"Atypical antipsychotics successfully treat schizophrenia and other conditions, with a lower incidence of extrapyramidal side effects than other agents used in treatment of these disorders."	1.32	Weight change after an atypical antipsychotic switch. ( Acholonu, WW; Bengtson, MA; Renner, BT; Ried, LD; Wilcox, BM, 2003)
"Psychopharmacology research aims to expand the therapeutic ratio between efficacy, on the one hand, and adverse events and safety, on the other."	1.31	Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. ( McIntyre, RS, 2002)
"The purpose of this case study is to document hepatic adverse effects associated with long-term risperidone use in pediatric populations."	1.30	Case study: risperidone-induced hepatotoxicity in pediatric patients. ( Briguglia, C; Grothe, D; Herion, D; Jacobsen, LK; Kumra, S, 1997)

Research

Studies (64)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Clinical Global Impressions-Bipolar Mania Improvement

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (6.25)	18.2507
2000's	41 (64.06)	29.6817
2010's	16 (25.00)	24.3611
2020's	3 (4.69)	2.80

Authors	Studies
Nicol, GE	1
Ivanov, I	1
Li, L	1
Yoo, ES	1
Li, X	2
Wyler, SC	1
Chen, X	1
Wan, R	1
Arnold, AG	1
Birnbaum, SG	1
Jia, L	1
Sohn, JW	1
Liu, C	1
Guber, KM	1
Cortes, ND	1
Duan, L	1
Li, S	1
Gao, Y	1
Lv, H	1
Zhang, M	1
Wang, L	1
Jiang, R	1
Xu, C	1
Wang, X	1
Gao, M	1
He, Y	1
Li, J	2
Li, WD	1
Anagnostou, E	1
Johnson, MS	1
Smith, DL	1
Li, Y	1
Kesterson, RA	1
Allison, DB	3
Nagy, TR	2
Jacobowitz, W	1
Derbabian, B	1
Saunders, A	1
Naarden, MT	1
Schuitemaker, A	1
Braakman, HM	1
van Doormaal, TP	1
Porro, GL	1
Straver, JS	1
Bonaccorso, S	1
Sodhi, M	1
Bobo, WV	1
Chen, Y	1
Tumuklu, M	1
Theleritis, C	1
Jayathilake, K	1
Meltzer, HY	1
Vasilenko, LM	1
Gorobets, LN	2
Bulanov, VS	1
Litvinov, AV	1
Ivanova, GP	1
Tsarenko, MA	1
Polyakovskaya, TP	1
Ronsley, R	1
Nguyen, D	1
Davidson, J	1
Panagiotopoulos, C	1
Baeza, I	2
Vigo, L	1
de la Serna, E	2
Calvo-Escalona, R	1
Merchán-Naranjo, J	3
Rodríguez-Latorre, P	1
Arango, C	3
Castro-Fornieles, J	1
Nolt, VD	1
Kibler, AV	1
Wilkening, GL	1
Fabian, TJ	1
Chang, KD	1
Findling, RL	1
McDougle, CJ	1
Stigler, KA	1
Erickson, CA	1
Posey, DJ	1
Fraguas, D	1
Laita, P	1
Parellada, M	2
Moreno, D	1
Ruiz-Sancho, A	1
Cifuentes, A	1
Giráldez, M	2
Kuzman, MR	1
Medved, V	1
Bozina, N	1
Hotujac, L	1
Sain, I	1
Bilusic, H	1
Dogangun, B	1
Bolat, N	1
Rustamov, I	1
Kayaalp, L	1
Zheng, L	1
Mack, WJ	1
Dagerman, KS	1
Hsiao, JK	1
Lebowitz, BD	1
Lyketsos, CG	1
Stroup, TS	1
Sultzer, DL	1
Tariot, PN	1
Vigen, C	1
Schneider, LS	1
Clark, D	1
Skrobot, OA	1
Adebiyi, I	1
Susce, MT	1
de Leon, J	1
Blakemore, AF	1
Arranz, MJ	1
Bond, DJ	1
Kauer-Sant'Anna, M	1
Lam, RW	1
Yatham, LN	1
Moreno, C	1
Alvarez, M	1
Alda, JA	1
Martínez-Cantarero, C	1
Sánchez, B	1
Goeb, JL	1
Marco, S	1
Duhamel, A	1
Kechid, G	1
Bordet, R	1
Thomas, P	1
Delion, P	1
Jardri, R	1
Fernández-Fernández, FJ	1
Rao, N	1
Venkatasubramanian, G	1
Korpade, V	1
Behere, R	1
Varambally, S	1
Gangadhar, B	1
Vitiello, B	1
Riddle, MA	1
Yenokyan, G	1
Axelson, DA	1
Wagner, KD	1
Joshi, P	1
Walkup, JT	1
Luby, J	1
Birmaher, B	1
Ryan, ND	1
Emslie, G	1
Robb, A	1
Tillman, R	1
McIntyre, RS	2
Atmaca, M	1
Kuloglu, M	1
Tezcan, E	1
Ustundag, B	1
Ried, LD	1
Renner, BT	1
Bengtson, MA	1
Wilcox, BM	1
Acholonu, WW	1
Ziegenbein, M	1
Kropp, S	1
Alméras, N	1
Després, JP	1
Villeneuve, J	1
Demers, MF	1
Roy, MA	1
Cadrin, C	1
Mottard, JP	1
Bouchard, RH	1
Schwenkreis, P	1
Assion, HJ	1
Lee, E	1
Leung, CM	1
Wong, E	1
Sahli, Ch	1
Bryois, Ch	1
Henderson, DC	1
Cagliero, E	1
Copeland, PM	1
Borba, CP	1
Evins, AE	1
Hayden, D	1
Weber, MT	1
Anderson, EJ	1
Daley, TB	1
Schoenfeld, D	1
Goff, DC	1
Vieweg, WV	1
Sood, AB	1
Pandurangi, A	1
Silverman, JJ	1
Brar, JS	1
Ganguli, R	1
Pandina, G	2
Turkoz, I	2
Berry, S	1
Mahmoud, R	1
Cope, MB	1
Fernández, JR	1
Geary, N	1
Casey, DE	1
Schooler, N	1
Rabinowitz, J	1
Davidson, M	1
Emsley, R	1
Harvey, PD	1
Kopala, L	1
McGorry, PD	1
Van Hove, I	1
Eerdekens, M	2
Swyzen, W	1
De Smedt, G	1
Ness-Abramof, R	1
Apovian, CM	1
Birkás Kováts, D	1
Palik, E	1
Faludi, G	1
Cseh, K	1
Meyer, JM	1
Bossie, CA	1
Greenspan, A	1
Reyes, M	1
Olah, R	1
Csaba, K	1
Augustyns, I	1
Lee, C	1
Wu, KH	1
Habil, H	1
Dyachkova, Y	1
Lee, P	1
Lin, EJ	1
Lee, NJ	1
Slack, K	1
Karl, T	1
Duffy, L	1
O'brien, E	1
Matsumoto, I	1
Dedova, I	1
Herzog, H	1
Sainsbury, A	1
Lin, SK	1
Chen, CK	1
Robinson, DG	1
Woerner, MG	1
Napolitano, B	1
Patel, RC	1
Sevy, SM	1
Gunduz-Bruce, H	1
Soto-Perello, JM	1
Mendelowitz, A	1
Khadivi, A	1
Miller, R	1
McCormack, J	1
Lorell, BS	1
Lesser, ML	1
Schooler, NR	1
Kane, JM	1
Neovius, M	1
Eberhard, J	1
Lindström, E	1
Levander, S	1
Kim, B	1
Kim, SJ	1
Son, JI	1
Joo, YH	1
Wooten, J	1
Afzal, KI	1
Briones, DF	1
DeVargas, C	1
Saddichha, S	1
Manjunatha, N	1
Ameen, S	1
Akhtar, S	1
Kolotkin, RL	1
Corey-Lisle, PK	1
Crosby, RD	1
Kan, HJ	1
McQuade, RD	1
Kumra, S	1
Herion, D	1
Jacobsen, LK	1
Briguglia, C	1
Grothe, D	1
Aquila, R	1
Emanuel, M	1
Wirshing, DA	1
Wirshing, WC	1
Kysar, L	1
Berisford, MA	1
Goldstein, D	1
Pashdag, J	1
Mintz, J	1
Marder, SR	1
Masand, PS	1
Jones, B	1
Basson, BR	1
Walker, DJ	1
Crawford, AM	1
Kinon, BJ	1
Simpson, MM	1
Goetz, RR	1
Devlin, MJ	1
Goetz, SA	1
Walsh, BT	1
Baptista, T	1
Webster, D	1
Devarajan, S	1
Gallant, J	1
Harris, A	1
Kopala, LC	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326]		120 participants (Anticipated)	Observational	2017-01-01	Recruiting
Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548]		450 participants	Interventional	2001-03-31	Completed
Treatment of Early Age Mania (TEAM) Study[NCT00057681]	Phase 3	379 participants (Actual)	Interventional	2003-02-28	Completed
Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504]	Phase 4	25 participants (Actual)	Interventional	2008-01-31	Completed
Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588]	Phase 4	60 participants (Actual)	Interventional	2010-06-30	Completed
A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366]		261 participants (Actual)	Interventional	2004-05-31	Completed
Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144]	Phase 4	71 participants (Actual)	Interventional	2016-09-30	Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.)
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700]	Phase 4	14 participants (Actual)	Interventional	2013-07-31	Terminated (stopped due to very slow recruitment, no sufficient results)
Metabolic Profile and Anthropometric Changes in Schizophrenia[NCT00534183]		2,006 participants (Actual)	Interventional	2006-06-30	Completed
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936]	Phase 4	16 participants (Actual)	Interventional	2005-12-31	Completed
Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562]	Phase 3	20 participants (Actual)	Interventional	2005-10-31	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00057681)
Timeframe: Measured at Week 8

K-SADS Mania Rating Scale

Intervention	units on a scale (Mean)
Randomized Medication - Lithium	2.49
Randomized Medication - Divalproex Sodium	2.73
Randomized Medication - Risperidone	1.70

The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64. (NCT00057681)
Timeframe: Measured at Week 8

Modified Side Effects Form for Children and Adolescents

Intervention	units on a scale (Mean)
Randomized Medication - Lithium	24.06
Randomized Medication - Divalproex Sodium	26.31
Randomized Medication - Risperidone	14.58

The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present. (NCT00057681)
Timeframe: Measured at Week 8

Change in Abdominal Fat (DEXA).

Intervention	side effects at week 8 (Mean)
Randomized Medication - Lithium	5.11
Randomized Medication - Divalproex Sodium	4.95
Randomized Medication - Risperidone	3.70

A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Change in Insulin Resistance as Measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

Intervention	g (Mean)
Ramelteon	3934.86
Placebo (Sugar Pill)	5120.92

A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Change in Waist Circumference

Intervention	HOMA score (Mean)
Ramelteon	2.4
Placebo (Sugar Pill)	2.36

A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Change in C-Reactive Protein (CRP) From Baseline to Week 12

Change in LDL-cholesterol Between Baseline and Week 12

Change in MATRICS Neuropsychological Battery Composite Score From Baseline to Week 12

Intervention	cm (Mean)
Ramelteon	106.09
Placebo (Sugar Pill)	108.37

Intervention	mg/L (Mean)
Pravastatin	0.8063
Placebo	-0.5136

Intervention	mg/dl (Mean)
Pravastatin	-25.565
Placebo	-2.913

"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12

Change in Positive and Negative Syndrome Scale (PANSS) General Score From Baseline to Week 12

Intervention	Scores on a scale (Mean)
Pravastatin	4.0417
Placebo	4.125

This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12

Change in Positive and Negative Syndrome Scale (PANSS) Negative Score From Baseline to Week 12

Intervention	Scores on a scale (Mean)
Pravastatin	-5.625
Placebo	-3.76

This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12

Change in Positive and Negative Syndrome Scale (PANSS) Positive Score From Baseline to Week 12

Intervention	Scores on a scale (Mean)
Pravastatin	-0.83
Placebo	-0.28

Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 12

Intervention	Scores on a scale (Mean)
Pravastatin	-2.9583
Placebo	-2.44

The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12

Change in Body Weight in Participants Assigned to Lorcaserin Monotherapy Treatment and Placebo

Intervention	Scores on a scale (Mean)
Pravastatin	-9.416
Placebo	-6.48

Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)

Change in Body Weight in Participants Assigned to Lorcaserin/Metformin Combination Treatment and Placebo

Intervention	pounds (Mean)
Lorcaserin	-5.18
Placebo	-3.02

Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)

Change in Fasting Glucose

Intervention	pounds (Mean)
Lorcaserin and Metformin	-13.05
Placebo	-3.02

fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)

Change in HDL Cholesterol

Intervention	mg/dL (Mean)
Lorcaserin and Metformin	-4.30
Lorcaserin	-3.27
Placebo	3.53

high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)

Change in Hemoglobin A1c

Intervention	mg/dL (Mean)
Lorcaserin and Metformin	3.8
Lorcaserin	1.45
Placebo	-0.78

glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)

Change in LDL Cholesterol

Intervention	percentage of glycosylated hemoglobin (Mean)
Lorcaserin and Metformin	-0.03
Lorcaserin	0.07
Placebo	0.05

low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)

Change in Total Cholesterol

Intervention	mg/dL (Mean)
Lorcaserin and Metformin	-7.60
Lorcaserin	-10.86
Placebo	-6.83

Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)

Change in Triglycerides

Intervention	mg/dL (Mean)
Lorcaserin and Metformin	-9.05
Lorcaserin	-13.45
Placebo	-9.21

serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)

Percent Weight Change Compared to Baseline Weight

BMI Percentile

BMI Z-scores

Weight Change

Change From Baseline in Body Mass Index (BMI)

Intervention	mg/dL (Mean)
Lorcaserin and Metformin	-18.60
Lorcaserin	-19.68
Placebo	-3.11

Intervention	percentage of weight change (Mean)
Ziprasidone	11.58
Aripiprazole, Quetiapine, Risperidone	5.66

Intervention	BMI percentile (Mean)
	baseline	week 12 (n=1, n=2)
Aripiprazole, Quetiapine, Risperidone	37.67	62.5
Ziprasidone	32	59

Intervention	BMI z-score (Mean)
	baseline	week 12 (n=1, n=2)
Aripiprazole, Quetiapine, Risperidone	-0.37	0.38
Ziprasidone	-0.51	0.22

Intervention	lbs (Mean)
	baseline	week 12 (n=1,2)
Aripiprazole, Quetiapine, Risperidone	118.5	141
Ziprasidone	120.5	151

Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Fasting Total Cholesterol

Intervention	kg/m^2 (Mean)
Aripiprazole	-0.4
Placebo	0.3

Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Intervention	mg/dL (Mean)
Aripiprazole	-3
Placebo	9

Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Low-density Lipoprotein (LDL)

Intervention	mg/dL (Mean)
Aripiprazole	0.4
Placebo	0.6

Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Triglycerides

Intervention	mg/dL (Mean)
Aripiprazole	-0.2
Placebo	3.1

Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Waist-hip Ratio (WHR)

Intervention	mg/dL (Mean)
Aripiprazole	-51.7
Placebo	47.6

Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Weight (Lbs)

Intervention	cm (Mean)
Aripiprazole	0.0
Placebo	0.0

Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Article	Year
Clinical trials in autism spectrum disorder: evidence, challenges and future directions. Current opinion in neurology, 2018, Volume: 31, Issue:2 Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz	2018
The use of atypical antipsychotics in pediatric bipolar disorder. The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders;	2008
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders;	2008
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 4 Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Chil	2008
Atypical antipsychotics and diabetes mellitus. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2004, Volume: 5, Issue:2 Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dibenzothiazepines; Glucose; Humans; Insul	2004
[Psychotropics and weight gain]. Praxis, 2004, Aug-25, Volume: 93, Issue:35 Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripi	2004
Metabolic effects of the atypical antipsychotics. Southern medical journal, 2007, Volume: 100, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepine	2007
Weight change and atypical antipsychotic treatment in patients with schizophrenia. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2 Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up	2001

Article	Year
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar disorders, 2015, Volume: 17, Issue:5 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass In	2015
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:7 Topics: Adolescent; Benzodiazepines; Blood Glucose; Body Mass Index; Child; Diagnostic and Statistical Manua	2008
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. The American journal of psychiatry, 2009, Volume: 166, Issue:5 Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met	2009
Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, Volume: 51, Issue:9 Topics: Adolescent; Age Factors; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit	2012
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:2 Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co	2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:2 Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co	2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:2 Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co	2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:2 Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co	2005
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. The American journal of psychiatry, 2005, Volume: 162, Issue:5 Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind	2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clinical therapeutics, 2005, Volume: 27, Issue:12 Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Blood Pressure; Body Mass Index; Bod	2005
Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. European child & adolescent psychiatry, 2006, Volume: 15, Issue:2 Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Body Mass Index; Child; Diagnostic	2006
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. The American journal of psychiatry, 2006, Volume: 163, Issue:12 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass Index; Female; Follo	2006
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11 Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Diagnosti	2007
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothi	2008
Novel antipsychotics: comparison of weight gain liabilities. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:6 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I	1999

Article	Year
Getting to Precision Psychopharmacology in Child Psychiatry: The Value of Adverse Treatment Effects. Journal of child and adolescent psychopharmacology, 2021, Volume: 31, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Child; Child Psychiatry; Drug-Related Side Effects and Adverse R	2021
The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. The Journal of experimental medicine, 2021, 07-05, Volume: 218, Issue:7 Topics: alpha-MSH; Animals; Antipsychotic Agents; Female; Hyperphagia; Hypothalamus; Male; Metabolic Syndrom	2021
Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More. Journal of child and adolescent psychopharmacology, 2022, Volume: 32, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Humans; Infant; Male	2022
T Psychoneuroendocrinology, 2018, Volume: 88 Topics: Adult; Antipsychotic Agents; Asian People; Benzodiazepines; Biomarkers, Pharmacological; Body Mass I	2018
Effects of risperidone on energy balance in female C57BL/6J mice. Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:9 Topics: Adipose Tissue, Brown; Animals; Antipsychotic Agents; Basal Metabolism; Brain-Derived Neurotrophic F	2013
The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications. Journal of psychosocial nursing and mental health services, 2014, Volume: 52, Issue:7 Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Caloric Restriction; Education, Nursing,	2014
[Idiopathic intracranial hypertension and obesity]. Nederlands tijdschrift voor geneeskunde, 2015, Volume: 159 Topics: Adolescent; Antipsychotic Agents; Female; Headache; Humans; Obesity; Pseudotumor Cerebri; Risperidon	2015
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:7 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Feeding and Eating Disorders; Fema	2015
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2015, Volume: 60, Issue:10 Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor	2015
The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. European child & adolescent psychiatry, 2017, Volume: 26, Issue:1 Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Child, Preschool; Female; Fol	2017
Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis. Paediatric drugs, 2017, Volume: 19, Issue:2 Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Female; Humans; Inpatients; Male; Metabol	2017
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry research, 2008, Sep-30, Volume: 160, Issue:3 Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepine	2008
Sibutramine-induced psychotic episode in an adolescent. Journal of psychosomatic research, 2008, Volume: 65, Issue:5 Topics: Adolescent; Antipsychotic Agents; Cyclobutanes; Humans; Kleine-Levin Syndrome; Male; Obesity; Psycho	2008
Contribution of leptin to the formation of neuroleptic obesity in patients with schizophrenia during antipsychotic therapy. Bulletin of experimental biology and medicine, 2008, Volume: 146, Issue:3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Leptin; Male; Obesity; Olan	2008
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. European psychiatry : the journal of the Association of European Psychiatrists, 2009, Volume: 24, Issue:7 Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes	2009
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Journal of affective disorders, 2010, Volume: 124, Issue:1-2 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Bod	2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar disorders, 2010, Volume: 12, Issue:2 Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Biomarkers; Bipolar Disorder; Body Mass Index; Ch	2010
[Metabolic side effects of risperidone in early onset schizophrenia]. L'Encephale, 2010, Volume: 36, Issue:3 Topics: Adolescent; Age Factors; Antipsychotic Agents; Body Mass Index; Child; Female; Humans; Hypercholeste	2010
Telmisartan and obesity. Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:19 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Humans; Obesity; PPAR d	2010
Risperidone treatment for polydipsia and hyponatremia in schizophrenia: a case report. Turk psikiyatri dergisi = Turkish journal of psychiatry, 2011,Summer, Volume: 22, Issue:2 Topics: Adult; Antipsychotic Agents; Female; Humans; Hyponatremia; Obesity; Polydipsia, Psychogenic; Risperi	2011
Antipsychotic drugs and diabetes. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Mar-18, Volume: 168, Issue:6 Topics: Antipsychotic Agents; Causality; Dementia; Diabetes Mellitus; Humans; Obesity; Risperidone; Weight G	2003
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:5 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dibenzothiazepines; Female	2003
Weight change after an atypical antipsychotic switch. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight;	2003
Risperidone-induced long-term weight gain in a patient with schizophrenia. The Australian and New Zealand journal of psychiatry, 2004, Volume: 38, Issue:3 Topics: Adult; Humans; Male; Obesity; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; W	2004
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:4 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Carrier State; Cholesterol, HDL; Coronary	2004
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:6 Topics: Adult; Antipsychotic Agents; Asian People; Benzodiazepines; Female; Hong Kong; Humans; Male; Obesity	2004
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of general psychiatry, 2005, Volume: 62, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine	2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of general psychiatry, 2005, Volume: 62, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine	2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of general psychiatry, 2005, Volume: 62, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine	2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of general psychiatry, 2005, Volume: 62, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine	2005
Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta psychiatrica Scandinavica, 2005, Volume: 111, Issue:3 Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Child; Child, Presc	2005
Antipsychotic drug-induced weight gain: development of an animal model. International journal of obesity (2005), 2005, Volume: 29, Issue:6 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Constitution; Body Weight; Dibenzothiazepines;	2005
Drug-induced weight gain. Timely topics in medicine. Cardiovascular diseases, 2005, Oct-28, Volume: 9 Topics: Anticonvulsants; Antipsychotic Agents; Humans; Obesity; Psychotropic Drugs; Risperidone; Valproic Ac	2005
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2005, Volume: 7, Issue:3 Topics: Antipsychotic Agents; Benzodiazepines; Carbohydrate Metabolism; Case-Control Studies; Clozapine; Dib	2005
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. The Australian and New Zealand journal of psychiatry, 2006, Volume: 40, Issue:5 Topics: Adult; Antipsychotic Agents; Asian People; Basal Ganglia Diseases; Benzodiazepines; Diagnostic and S	2006
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology, 2006, Volume: 51, Issue:7-8 Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli	2006
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesit	2006
Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta psychiatrica Scandinavica, 2007, Volume: 115, Issue:4 Topics: Adult; Aged; Antipsychotic Agents; Body Weight; Female; Follow-Up Studies; Humans; Male; Middle Aged	2007
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. Journal of affective disorders, 2008, Volume: 105, Issue:1-3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Drug A	2008
Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female. CNS spectrums, 2007, Volume: 12, Issue:11 Topics: Abdominal Pain; Adolescent; Bipolar Disorder; Drinking Behavior; Feeding Behavior; Female; Galactorr	2007
Case study: risperidone-induced hepatotoxicity in pediatric patients. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, Volume: 36, Issue:5 Topics: Adolescent; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Child; Female; Humans; Mal	1997
Weight gain and antipsychotic medications. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:5 Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid	1999
Relative weight gain among antipsychotics. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:10 Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid	1999
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:9 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu	2001
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 3 Topics: Anticonvulsants; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Female; Fructose; Humans; La	2002
Mechanisms of weight gain induced by antipsychotic drugs. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:3 Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Appetite; Dopamine Antagoni	2002
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations. Schizophrenia research, 2002, Jul-01, Volume: 56, Issue:1-2 Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Follow-Up Stud	2002

risperidone and Obesity